Author(s): Forslund T, Raaschou P, Hjemdahl P, Krakau I, Wettermark B
Abstract Share this page
Abstract Purpose. To investigate the use of the weight-loss drugs rimonabant, sibutramine, and orlistat in primary care and to characterize the patients receiving the drugs. Methods. In this retrospective, descriptive study, 300 randomly selected patients having started weight-loss drug treatment at 15 primary care centres were investigated using the patient's medical records and their complete drug purchase data. Results. Even though 48\% of the patients specifically demanded drug treatment, 77\% continued treatment less than one year. 28\% of rimonabant patients and 32\% of sibutramine patients had a history of depression or antidepressant treatment. 41\% of sibutramine patients had a history of hypertension and/or cardiovascular disease. 36\% had no documented weight after treatment initiation. Conclusions. These results suggest that weight-loss drug treatment was often initiated upon patient request but was of limited clinical benefit as it was managed in a large portion of Swedish primary carecenters.
This article was published in J Obes
and referenced in Journal of Pharmaceutical Care & Health Systems